 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | AdCLD-CoV19 / Cellid
Journal: Dose-dependent serological profiling of AdCLD-CoV19-1 vaccine in adults. (Pubmed Central) - Jan 28, 2025
Using a systems serology approach, we demonstrated significant dose-dependent differences in the humoral immune responses induced by the AdCLD-CoV19-1 chimeric adenovirus-based severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, particularly against the SARS-CoV-2 spike 2 domain. These findings highlight the importance of assessing not only neutralizing antibody titers but also the quality and functionality of antibody responses when evaluating vaccine efficacy.
- | AdCLD-CoV19 / Cellid
Preclinical, Journal: Boosting with variant-matched adenovirus-based vaccines promotes neutralizing antibody responses against SARS-CoV-2 Omicron sublineages in mice. (Pubmed Central) - Mar 4, 2024
Previously, we developed AdCLD-CoV19-1, a non-replicating recombinant adenoviral vector that encodes the receptor binding domain of the spike protein of the ancestral SARS-CoV-2 strain...Of note, boosting with a vaccine targeting the BA.1 or BA.2 Omicron subvariant was most effective in neutralization against the pseudo-virus of BA.2.75 strain, whereas BA.4.1/5-adapted booster shots were most effective in neutralization against BQ.1, BQ1.1, and BF.7. Therefore, it is imperative to develop a vaccination strategy that can cover the unique spike mutations of currently circulating Omicron subvariants to prevent the next wave of COVID-19.
- | AdCLD-CoV19 / Cellid
Journal: Strategy to develop broadly effective multivalent COVID-19 vaccines against emerging variants based on Ad5/35 platform. (Pubmed Central) - Mar 1, 2024
We developed bivalent vaccine AdCLD-CoV19-1 BA.5/BA.2.75 and trivalent vaccines AdCLD-CoV19-1 XBB/BN.1/BQ.1.1 and AdCLD-CoV19-1 XBB.1.5/BN.1/BQ.1.1 using an Ad5/35 platform-based non-replicating recombinant adenoviral vector...We found that the BA.5/BA.2.75 bivalent and the XBB/BN.1/BQ.1.1 and XBB.1.5/BN.1/BQ.1.1 trivalent vaccines exhibited improved cross-neutralization ability compared to their respective monovalent vaccines. These data suggest that the developed multivalent vaccines enhance immunity against circulating Omicron subvariants and effectively elicit neutralizing antibodies across a broad spectrum of SARS-CoV-2 variants.
- || AdCLD-CoV19 / Cellid
Trial completion: Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers (clinicaltrials.gov) - Jul 31, 2023
P1, N=40, Completed, Sponsor: Cellid Co., Ltd.
These data suggest that the developed multivalent vaccines enhance immunity against circulating Omicron subvariants and effectively elicit neutralizing antibodies across a broad spectrum of SARS-CoV-2 variants. Active, not recruiting --> Completed
- ||| AdCLD-CoV19 / Cellid
Trial completion: Safety and Immunogenicity Study of AdCLD-CoV19: A COVID-19 Preventive Vaccine in Healthy Volunteers (clinicaltrials.gov) - Jul 31, 2023
P2a, N=150, Completed, Sponsor: Cellid Co., Ltd.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | AdCLD-CoV19 / Cellid
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: Safety and Immunogenicity of COVID-19 Vaccine, AdCLD-CoV19-1 (clinicaltrials.gov) - Jun 22, 2023
P2b, N=4, Terminated, Sponsor: Cellid Co., Ltd.
Active, not recruiting --> Completed N=200 --> 4 | Trial completion date: May 2024 --> Nov 2022 | Not yet recruiting --> Terminated | Trial primary completion date: May 2024 --> Nov 2022; Study early terminated based on the sponsor(manufacture)'s decision
- | AdCLD-CoV19 / Cellid
Trial completion date: Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers (clinicaltrials.gov) - Feb 8, 2023
P1, N=40, Active, not recruiting, Sponsor: Cellid Co., Ltd.
N=200 --> 4 | Trial completion date: May 2024 --> Nov 2022 | Not yet recruiting --> Terminated | Trial primary completion date: May 2024 --> Nov 2022; Study early terminated based on the sponsor(manufacture)'s decision Trial completion date: Dec 2022 --> May 2023
- | AdCLD-CoV19 / Cellid
Trial completion date: Safety and Immunogenicity Study of AdCLD-CoV19: A COVID-19 Preventive Vaccine in Healthy Volunteers (clinicaltrials.gov) - Feb 8, 2023
P2a, N=150, Active, not recruiting, Sponsor: Cellid Co., Ltd.
Trial completion date: Dec 2022 --> May 2023 Trial completion date: Dec 2022 --> May 2023
- | AdCLD-CoV19 / Cellid
Trial completion date, Trial primary completion date: Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers (clinicaltrials.gov) - Oct 5, 2022
P1, N=40, Active, not recruiting, Sponsor: Cellid Co., Ltd.
Trial completion date: Dec 2022 --> May 2023 Trial completion date: Sep 2022 --> Dec 2022 | Trial primary completion date: Sep 2022 --> Dec 2022
- ||||| AdCLD-CoV19 / Cellid
New P2b trial: Safety and Immunogenicity of COVID-19 Vaccine, AdCLD-CoV19-1 (clinicaltrials.gov) - Aug 30, 2022
P2b, N=200, Not yet recruiting, Sponsor: International Vaccine Institute
- | AdCLD-CoV19 / Cellid
Trial completion date: Safety and Immunogenicity Study of AdCLD-CoV19: A COVID-19 Preventive Vaccine in Healthy Volunteers (clinicaltrials.gov) - Aug 12, 2022
P2a, N=150, Active, not recruiting, Sponsor: Cellid Co., Ltd.
Trial completion date: Sep 2022 --> Dec 2022 | Trial primary completion date: Sep 2022 --> Dec 2022 Trial completion date: Apr 2022 --> Dec 2022
- | AdCLD-CoV19 / Cellid
Preclinical, Journal: The Chimeric Adenovirus (Ad5/35) Expressing Engineered Spike Protein Confers Immunity against SARS-CoV-2 in Mice and Non-Human Primates. (Pubmed Central) - May 30, 2022
While AdCLD-CoV19 maintained neutralizing antibody activity against various SARS-CoV-2 variants, it was reduced to single vaccination for β and ο variants, and the reduced neutralizing antibody activity was restored with booster shots. Hence, AdCLD-CoV19 can prevent SARS-CoV-2 with a single vaccination, and the new vaccine administration strategy that responds to various variants can maintain the efficacy of the vaccine.
- || AdCLD-CoV19 / Cellid
Enrollment closed: Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers (clinicaltrials.gov) - Jan 24, 2022
P1, N=40, Active, not recruiting, Sponsor: Cellid Co., Ltd.
Hence, AdCLD-CoV19 can prevent SARS-CoV-2 with a single vaccination, and the new vaccine administration strategy that responds to various variants can maintain the efficacy of the vaccine. Recruiting --> Active, not recruiting
- || AdCLD-CoV19 / Cellid
New P1 trial: Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers (clinicaltrials.gov) - Sep 17, 2021
P1, N=40, Recruiting, Sponsor: Cellid Co., Ltd.
- || AdCLD-CoV19 / Cellid
Enrollment closed, Trial primary completion date: Safety and Immunogenicity Study of AdCLD-CoV19: A COVID-19 Preventive Vaccine in Healthy Volunteers (clinicaltrials.gov) - Jul 28, 2021
P2a, N=150, Active, not recruiting, Sponsor: Cellid Co., Ltd.
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2021 --> Jul 2021
- ||| AdCLD-CoV19 / Cellid
Enrollment open: Safety and Immunogenicity Study of AdCLD-CoV19: A COVID-19 Preventive Vaccine in Healthy Volunteers (clinicaltrials.gov) - Jan 4, 2021
P2a, N=150, Recruiting, Sponsor: Cellid Co., Ltd.
Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2021 --> Jul 2021 Not yet recruiting --> Recruiting
- |||| AdCLD-CoV19 / Cellid
New P2a trial: Safety and Immunogenicity Study of AdCLD-CoV19: A COVID-19 Preventive Vaccine in Healthy Volunteers (clinicaltrials.gov) - Dec 13, 2020
P2a, N=150, Not yet recruiting, Sponsor: Cellid Co., Ltd.